The Basic Biology of PP2A in Hematologic Cells and Malignancies.

Front Oncol

Laboratory of Protein Phosphorylation and Proteomics, Department Cellular and Molecular Medicine, University of Leuven, Leuven , Belgium.

Published: January 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Reversible protein phosphorylation plays a crucial role in regulating cell signaling. In normal cells, phosphoregulation is tightly controlled by a network of protein kinases counterbalanced by several protein phosphatases. Deregulation of this delicate balance is widely recognized as a central mechanism by which cells escape external and internal self-limiting signals, eventually resulting in malignant transformation. A large fraction of hematologic malignancies is characterized by constitutive or unrestrained activation of oncogenic kinases. This is in part achieved by activating mutations, chromosomal rearrangements, or constitutive activation of upstream kinase regulators, in part by inactivation of their anti-oncogenic phosphatase counterparts. Protein phosphatase 2A (PP2A) represents a large family of cellular serine/threonine phosphatases with suspected tumor suppressive functions. In this review, we highlight our current knowledge about the complex structure and biology of these phosphatases in hematologic cells, thereby providing the rationale behind their diverse signaling functions. Eventually, this basic knowledge is a key to truly understand the tumor suppressive role of PP2A in leukemogenesis and to allow further rational development of therapeutic strategies targeting PP2A.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263090PMC
http://dx.doi.org/10.3389/fonc.2014.00347DOI Listing

Publication Analysis

Top Keywords

hematologic cells
8
tumor suppressive
8
basic biology
4
pp2a
4
biology pp2a
4
pp2a hematologic
4
cells
4
cells malignancies
4
malignancies reversible
4
protein
4

Similar Publications

Cereblon upregulation overcomes thalidomide resistance in multiple myeloma through mitochondrial functional reprogramming.

BMB Rep

September 2025

Basic Research Laboratory, Department of Physiology, College of Medicine, Smart Marine Therapeutic Center, Cardiovascular and Metabolic Disease Core Research Center, Inje University, Busan 47392, Korea; Department of Health Science and Technology, College of Medicine, Inje University, Busan 47392, K

Patients with multiple myeloma develop resistance to thalidomide during therapy, and the mechanisms to counteract thalidomide resistance remain elusive. Here, we explored the interaction between cereblon and mitochondrial function to mitigate thalidomide resistance in multiple myeloma. Measurements of cell viability, ATP production, mitochondrial membrane potential, mitochondrial ROS, and protein expression via western blotting were conducted in vitro using KSM20 and KMS26 cells to assess the impact of thalidomide on multiple myeloma.

View Article and Find Full Text PDF

Cancer is one of the major public health challenges worldwide, and the STAT3 signaling pathway is recognized as one of the most important signaling pathways in the progression of this disease. This pathway can increase the survival and proliferation of cancer cells and their resistance to treatment by regulating lipid and carbohydrate metabolism, apoptosis, and inflammatory processes. Therefore, STAT3 inhibition is considered an effective therapeutic approach in the fight against cancer.

View Article and Find Full Text PDF

Introduction: Conventional dendritic cells (cDCs) in the gut express the vitamin A (VA)-converting enzyme retinal dehydrogenase 2 (RALDH2) and produce significant amounts of retinoic acid (RA). RA derived from gut cDCs contributes to the generation of tolerogenic responses by promoting Treg differentiation while inhibiting Th1 and Th17 cell differentiation. In this study, we investigated whether similar RA-mediated immunoregulatory mechanisms operate in the pancreas using an experimental autoimmune pancreatitis (AIP) model.

View Article and Find Full Text PDF

Aim: The objective of this study was to describe the disease management landscape for patients with mantle cell lymphoma (MCL) in Japan.

Methods: We conducted a cross-sectional survey with retrospective data capture of physicians and their consulting patients between March and December 2022. Physicians completed patient record forms in a 1:2 ratio: one patient receiving first-line (1 L) treatment and two patients with relapsed/refractory disease, one of whom must have received and discontinued a Bruton's tyrosine kinase inhibitor (BTKi).

View Article and Find Full Text PDF

Grafting of Resveratrol-Chitosan Nanoparticles as a Promising Radiosensitizer and Protector in DMBA-Induced Breast Cancer in Mice.

Curr Cancer Drug Targets

September 2025

Department of Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Menoufia, Egypt.

Introduction: Breast cancer is the most common malignancy among women and the second leading cause of cancer-related deaths worldwide. Resveratrol, a polyphenolic stilbene derivative found in grapes, red wine, and other plants, possesses anti-cancer properties. Various studies have reported the potential of different nanomaterials to act as radiosensitizers against tumor cells.

View Article and Find Full Text PDF